Payment overview · 2025
General Payments
$290.07
5 reported records · 3 companies
Healthcare provider profile · identity verified
Maher Kassis, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · IRVINE, KY · NPI 1912968603
Verified facts
What the public records show
CMS Open Payments records show Maher Kassis, M.D. received $290.07 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 87.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $254.38 | 87.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.33 | 7.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.36 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $290.07 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $254.38 | 3 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 278 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
278 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 844 | 171 |
| Pantoprazole Sodium | Pantoprazole Sodium | 784 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 759 | 136 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 682 | 124 |
| Gabapentin | Gabapentin | 668 | 108 |
| Lisinopril | Lisinopril | 555 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 507 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 456 | 100 |
| Furosemide | Furosemide | 449 | 103 |
| Duloxetine Hcl | Duloxetine Hcl | 433 | 81 |
| Montelukast Sodium | Montelukast Sodium | 429 | 83 |
| Metformin Hcl | Metformin Hcl | 386 | 76 |
| Omeprazole | Omeprazole | 353 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 316 | 67 |
| Eliquis | Apixaban | 314 | 46 |
| Alprazolam | Alprazolam | 302 | 55 |
| Carvedilol | Carvedilol | 294 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 63 |
| Sertraline Hcl | Sertraline Hcl | 290 | 51 |
| Ozempic | Semaglutide | 278 | 45 |
| Jardiance | Empagliflozin | 256 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 254 | 51 |
| Doxazosin Mesylate | Doxazosin Mesylate | 220 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 216 | 61 |
| Donepezil Hcl | Donepezil Hcl | 215 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 214 | 37 |
| Finasteride | Finasteride | 214 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 202 | 49 |
| Losartan Potassium | Losartan Potassium | 199 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 180 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 44 |
| Allopurinol | Allopurinol | 171 | 34 |
| Trazodone Hcl | Trazodone Hcl | 160 | 30 |
| Famotidine | Famotidine | 159 | 30 |
| Glipizide | Glipizide | 155 | 37 |
| Potassium Chloride | Potassium Chloride | 153 | 32 |
| Tradjenta | Linagliptin | 150 | 25 |
| Memantine Hcl | Memantine Hcl | 137 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 135 | 24 |
| Buspirone Hcl | Buspirone Hcl | 127 | 25 |
| Nystatin | Nystatin | 125 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 122 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 122 | 28 |
| Xarelto | Rivaroxaban | 121 | 16 |
| Simvastatin | Simvastatin | 116 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 22 |
| Prednisone | Prednisone | 112 | 82 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 111 | 23 |
| Clonazepam | Clonazepam | 108 | suppressed |
| Cefdinir | Cefdinir | 107 | 73 |
| Amitriptyline Hcl | Amitriptyline Hcl | 99 | 15 |
| Clonidine Hcl | Clonidine Hcl | 99 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 17 |
| Linzess | Linaclotide | 92 | 19 |
| Lorazepam | Lorazepam | 91 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 90 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 19 |
| Midodrine Hcl | Midodrine Hcl | 84 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 83 | 15 |
| Nitroglycerin | Nitroglycerin | 83 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 16 |
| Ezetimibe | Ezetimibe | 82 | 18 |
| Meloxicam | Meloxicam | 82 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 82 | 17 |
| Bumetanide | Bumetanide | 81 | 16 |
| Diazepam | Diazepam | 80 | 17 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 74 | 17 |
| Myrbetriq | Mirabegron | 73 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 12 |
| Januvia | Sitagliptin Phosphate | 67 | 11 |
| Propranolol Hcl | Propranolol Hcl | 64 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 63 | 14 |
| Spironolactone | Spironolactone | 63 | 15 |
| Atenolol | Atenolol | 61 | 13 |
| Baclofen | Baclofen | 59 | 13 |
| Tramadol Hcl | Tramadol Hcl | 59 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 13 |
| Methocarbamol | Methocarbamol | 55 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 13 |
| Ondansetron Odt | Ondansetron | 52 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | suppressed |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Pregabalin | Pregabalin | 50 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 11 |
| Temazepam | Temazepam | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 15 |
| Metformin Hcl Er | Metformin Hcl | 48 | 11 |
| Promethazine Hcl | Promethazine Hcl | 47 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 43 | 43 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 38 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 17 |
| Primidone | Primidone | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | 14 |
| Vascepa | Icosapent Ethyl | 42 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | suppressed |
| Loperamide | Loperamide Hcl | 38 | 17 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 31 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Colchicine | Colchicine | 35 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 18 |
| Fentanyl | Fentanyl | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 12 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 17 |
| Fluconazole | Fluconazole | 26 | 19 |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 15 |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Corlanor | Ivabradine Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 16 |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Phenytoin | Phenytoin | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Donepezil Hcl Odt | Donepezil Hcl | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $290.07 · 5 records | Novo Nordisk Inc | MAVYRET, OTEZLA, Ozempic, REPATHA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error